LONDON (Alliance News) - LiDCO Group PLC said Wednesday that a study into the cost-effectiveness of Postoperative Goal-Directed Therapy proved that this type of care was both cost and clinically effective, supporting the use of its LiDCOplus monitoring equipment.
The LiDCOplus monitor provides continuous measurement of oxygen delivery, which is minimally invasive as it requires only peripheral artery and vein access, meaning there's no need for a central venous catheter or catheter inserted into the heart of major artery.
The study, "A Cost-Effectiveness Analysis of Postoperative Goal-Directed Therapy (GDT) for High-Risk Surgical Patients", was authored by Claudia Ebm and others and published in the journal Critical Care Medicine.
LiDCO noted that clinicians from St George's Hospital have been delivering GDT using its monitory for the last eight years. The data from the study showed that in a short-term model GDT reduced costs by GBP2,631.77 per patient and by GBP2,134.86 per hospital survivor.
In the long term, GDT was shown to prolong quality-adjusted life expectancy by 9.8 months and bring incremental cost savings of GBP1,285.77.
Shares in LiDCO were trading unchanged at 18.75 pence Wednesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
